Dexcom, Inc. Public Equity Report

• Company: Dexcom, Inc.
• Ticker: DXCM
• Exchange: Nasdaq
• Report Date: 2026-07-31
• Data Cutoff: Q2 2026 results filed 2026-07-30
• Evidence Confidence: MEDIUM
• Research Stance: Constructive; BUY

Decision Snapshot

Dexcom enters the second half of 2026 with a constructive operating setup: Q2 revenue reached USD 1.31 billion, gross margin was 63.4%, and operating margin was 24.3%. The central decision hinge is whether product and access expansion can sustain double-digit growth while the latest cash-flow softness proves temporary. The accepted public baseline comes from Dexcom's Q2 Form 10-Q filed on 2026-07-30: https://www.sec.gov/Archives/edgar/data/1093557/000109355726000143/dxcm-20260630.htm.

This stance is conditional rather than unconditional. Stronger revenue, margin, and product-quality evidence would reinforce it; weaker growth, renewed margin pressure, or persistent cash conversion weakness would challenge it.

Company and Business Overview

Dexcom develops and commercializes continuous glucose monitoring systems. The economic question is whether broader access and product cadence can expand the addressable user base while scale supports durable margins and cash generation. The public evidence establishes a scaled, profitable business, but it does not eliminate execution, product-quality, reimbursement, or competitive risk. Source: Dexcom Q2 2026 Form 10-Q, filed 2026-07-30: https://www.sec.gov/Archives/edgar/data/1093557/000109355726000143/dxcm-20260630.htm.

Thesis and Variant View

The constructive thesis is that access expansion, G7 15-Day, Stelo, and the G8 development path can sustain adoption while operating leverage improves. The variant view is that the market may underweight the combination of double-digit revenue growth and material year-over-year margin expansion.

The counter-view is that strong reported margins may not translate into durable cash compounding if competitive intensity, reimbursement pressure, quality remediation, or working-capital demands rise. The thesis is falsifiable: it weakens if revenue falls below the proposed USD 1.15 billion warning gate, gross margin falls below 60%, operating margin falls below 17%, or free cash flow turns negative.

Business Quality and Moat

Dexcom's business quality rests on sensor performance, user experience, clinical integration, coverage, and a recurring supply model. Product cadence and broader access can reinforce the franchise, while quality failures or a loss of payer and user confidence can impair it quickly. Confidence in moat durability would strengthen with continued adoption, stable or improving margins, and reliable product execution; it would weaken with sustained pricing pressure, share loss, or material quality events.

Operating KPI Baseline

These gates are analyst-proposed research thresholds, not company guidance. Baselines and lineage are drawn from the Q2 2026 filing: https://www.sec.gov/Archives/edgar/data/1093557/000109355726000143/dxcm-20260630.htm.

Growth Drivers

• Access expansion: Broader coverage and adoption beyond intensive-insulin users can enlarge the addressable base.
• Product cadence: G7 15-Day, Stelo, and the G8 development path can improve reach, experience, and retention.
• Operating leverage: Sustained gross margin near or above 63% and operating margin near or above 20% would support earnings durability.
• Cash conversion: Reacceleration in operating and free cash flow would make reported profit improvement more credible.

The growth case strengthens when adoption, revenue, margins, product reliability, and cash conversion improve together.

Valuation and Scenarios

The retained intrinsic FCFF scenarios and their assumptions appear in the dedicated scenario table below.

Risks, Catalysts, and Falsifiers

Monitoring Plan

Review each quarterly filing and public earnings release against these questions:

1. Does quarterly revenue remain at or above USD 1.25 billion, and is year-over-year growth still double digit?
2. Are gross margin and operating margin holding above the 63% and 20% confirmation gates?
3. Is cash conversion improving rather than diverging further from reported profit?
4. Are product quality, access, and competitive disclosures strengthening or weakening?
5. Has diluted share count remained below 400.0 million shares?

Escalate the review if two warning gates trigger together or if any single break gate is accompanied by a material product-quality event.

Public Sources

• Dexcom Q2 2026 Form 10-Q, filed 2026-07-30: Revenue, profitability, balance-sheet, cash-flow, share-count, and risk baselines. https://www.sec.gov/Archives/edgar/data/1093557/000109355726000143/dxcm-20260630.htm
• SEC company facts for Dexcom, accessed through accepted quarterly lineage: Historical reported financial observations and period comparisons. https://data.sec.gov/api/xbrl/companyfacts/CIK0001093557.json

This public report uses redistributable public-primary evidence only. It excludes licensed research, private context, and live market data. It is informational research, not personalized investment advice.

Quarterly KPI Trajectory

The public-safe 12-quarter trajectory covers FY2023 Q3 through FY2026 Q2 and preserves explicit source gaps rather than estimating missing values. In Q2 2026, revenue was USD 1.31 billion and increased 13.1% year over year (Revenue — FY2026Q2 — USD 1.31 billion); gross margin reached 63.4%, up 391 basis points (Gross margin — FY2026Q2 — 0.63 ratio); and operating margin reached 24.3%, up 595 basis points (Operating margin — FY2026Q2 — 0.24 ratio).

Operating income increased 49.7% year over year (Operating income / EBIT — FY2026Q2 — USD 318.3 million) and net income attributable to common shareholders increased 38.5% (Net income attributable to common — FY2026Q2 — USD 249.1 million). The counter-signal is cash conversion: quarterly operating cash flow declined 11.2% (Operating cash flow — FY2026Q2 — USD 269.2 million) and free cash flow declined 11.7% (Free cash flow — FY2026Q2 — USD 184.5 million). Forty-one unavailable quarterly observations remain explicit evidence gaps.

Earnings Driver Bridge

The deterministic earnings bridge is not public because not every input and driver has dated, redistributable primary-source lineage. No public waterfall is shown; the report therefore relies on reported GAAP trajectories and explicitly avoids attributing every line change to a single cause.

Acquisition Effects

No acquisition-effect record was detected in the accepted public handoff. Recurring, one-off, accounting, financing, tax, and synergy effects therefore remain an evidence gap rather than an inferred bridge.

Management Explanations and Persistence

The accepted Q2 filing reports the GAAP measures but does not quantify a complete driver bridge for every line. The public handoff retains this as an analyst-identified evidence limitation (Management driver — FY2026Q2 — unknown: The accepted Q2 filing reports the GAAP measures but does not provide a quantified driver bridge for every line; the related move is retained as an explicit unexplained reported change rather than attributed to a single cause.), not as a management explanation. Persistence is classified as unknown until dated public-primary evidence supports a temporary or structural classification.

Expectations and Material Q&A

Pre-release redistributable expectations and material public Q&A records are unavailable in the accepted public handoff. Any licensed or non-redistributable context is withheld, and no consensus comparison is inferred.

Management Language Changes

Comparable public-primary language-change records are unavailable in the accepted public handoff. Introduced, removed, strengthened, softened, or delayed language is therefore an explicit evidence gap, not an inferred signal.